Just months after it started trading on the Nasdaq in June 2021, the company was valued as high as $5.8 billion. As of Friday ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

Fungi-focused biotech LifeMine Therapeutics is slimming down its staff and consolidating its operations to dig into clinical ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

In a welcome move, GSK ADR saw its Relative Strength Rating improve from 69 to 75 on Monday. Please watch the video at ...

Almost £8bn has been wiped off the value of the world’s biggest drugmakers after America’s leading vaccine official was ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...

Pfizer delayed the announcement of its COVID-19 vaccine until after the 2020 election when it thought Donald Trump was defeated.

Brace! That’s the only word needed to sum up the feeling around the globe today as everyone gears up for Trump’s Reshape the ...

The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...

Moderna stock dips 10% amid FDA resignation, signaling regulatory risks. Strong cash reserves can't offset competitive and ...